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SUMMARY
Low-density lipoprotein receptor-related protein-1 (LRP1) is a ubiquitous membrane receptor functioning as a scavenger and regulatory receptor, inducing anti-inflammatory and prosurvival signals. Based on the known structure-activity of the LRP1 receptor binding site, the authors synthesized a small peptide (SP16). SP16 induced a >50% reduction in infarct size (p < 0.001) and preservation of left ventricular systolic function (p < 0.001), and treatment with an LRP1 blocking antibody eliminated the protective effects of SP16. In conclusion, LRP1 activation with SP16 given within 30 min of reperfusion during experimental acute myocardial infarction leads to a cardioprotective signal reducing infarct size and preservation of cardiac systolic function. Low-density lipoprotein receptor-related protein-1 (LRP1) is a ubiquitous membrane receptor functioning as a scavenger and regulatory receptor (3) (4) (5) . Its expression increases during hypoxia, ischemia, and tissue injury (3) (4) (5) (6) . LRP1 is a nonselective receptor, binding several plasma proteins (3) (4) (5) (6) . Also known as an alpha-2-macroglobulin (A2MG) receptor, LRP1 has the ability to bind the complex of A2MG and plasma proteases (7, 8) . The binding of the protease-inhibitor complex to LRP1 is seen across the entire spectrum of serine protease inhibitors (SERPINs) such as alpha-1 antitrypsin (AAT) and antithrombin III (AT III ), and referred to as a SERPINenzyme complex (SEC) receptor (3) (4) (5) The binding of protease-inhibitor complexes to LRP1 inhibits the inflammatory response (5) and induces a prosurvival signal through phosphorylation of protein kinase Akt (9) . In preclinical animal studies, the administration of plasma-derived AAT or AT III led to a significant reduction in myocardial injury in experimental acute myocardial infarction (AMI) (10, 11) . Therefore, we hypothesized that the synthesis of an LRP1 agonist in the form of a small peptide would provide cardioprotection in AMI.
METHODS
SYNTHESIS OF THE LRP1 AGONIST. SERPINs are a family of proteins characterized by the ability to inhibit plasma serine proteases such as trypsin, elastase, thrombin, and others (12) . When SERPINs bind the serine proteases and consequently inactivate them, a conformational change occurs by which a short peptide containing a unique motif (5 to 11 amino acids) is exposed (13) . This unique motif is responsible for the binding to LRP1 (3, 14) . Based on the known structureactivity of the LRP1 receptor binding site, we synthe- Toldo et al. After an 18-to 24-h incubation at 37 C, 20 ml of supernatant was transferred to 180 ml of QUANTI-Blue 
ASSESSMENT OF LRP1 EXPRESSION IN THE HEART.
We investigated the expression of LRP1 in the hearts of 6 patients with ischemic heart failure undergoing heart transplant using western blot, and 6 subjects who had died of traumatic death and free of cardiac In a final set of experiments we treated 4 to 6 mice with SP16 administered a single dose of 3, 10, 100, or 500 mg given subcutaneously after reperfusion, to test the clinical value of this delivery route.
ASSESSMENT OF SURVIVAL AND DEATH SIGNALS.
To assess Akt signaling by western blot, we took the heart of 9 mice that had underwent surgery for myocardial ischemia (30 min) followed by reperfusion were performed using analysis of variance, followed was considered significant. Toldo et al.
RESULTS
SYNTHESIS OF THE LRP1 AGONIST. Based on the known structure-activity of the LRP1 receptor binding site, we synthesized a small peptide designated SP16. The structure for SP16 is depicted in Figure 1 .
SP16 was shown to bind to LRP1 in vitro, whereas SP34 did not (Figure 1) .
Pharmacokinetics of SP16 obtained in rats revealed maximum plasma concentrations of 1.5 mg/ml, 16.4 mg/ml, and 5.8 mg/ml when measured after 5 mg/kg IV bolus, 25 mg/kg IV bolus, and 25 mg/kg IV infusion, respectively. SP16 pharmacokinetics were characterized by rapid initial clearance (216 ml$min 
ANTI-INFLAMMATORY EFFECTS OF SP16 IN VIVO.
We tested the effects of SP16 in a mouse model of endotoxemia. SP16 peptide was given in 3 doses of 4 mg intraperitoneally at -2, 0, and þ0.5 h before highdose LPS challenge (15 mg/kg) significantly decreased mortality at 72 h from 100% to 40% (p < 0.001) (Supplemental Figure 2) , thus confirming preservation of the LRP1 agonist activity in vivo.
LRP1 EXPRESSION IS INCREASED IN THE HEART
AFTER AMI. We measured expression of LRP1 in the heart of 6 male patients with ischemic heart disease undergoing heart transplantation (median 61 [range 47 to 67] years of age, 3 patients were supported by a LV assist device before transplant, 1 patient had a total artificial heart, and 2 had direct transplantation). Figure 2 shows a >2-fold increase in LRP1 expression in the hearts of patients versus control patients (p < 0.001). We also measured LRP1 expression in the heart of mice 24 h after ischemia-reperfusion injury. 
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Toldo et al. at rest and after challenge with isoproterenol to evaluate also contractile reserve. As shown in Figure 5 , SP16 had no significant effect on LVFS % at rest or after isoproterenol challenge. These data show that, as tested, SP16 has no appreciable inotropic activity in vivo.
We also measured LVFS % at 7 days after AMI in We measured phosphorylation at Ser473 of Akt in myocardial samples during ischemiareperfusion as a measure of the prosurvival effect of SP16. As compared with vehicletreated mice, mice receiving SP16 100 mg intraperitoneally at time of reperfusion had a significant increase in pAkt/total Akt ratio, associated with a reduction in the ratio of the proapoptotic to antiapoptotic Bax/Bcl2 ratio and of caspase-3 myocardial tissue
DISCUSSION
The data presented herein show that SP16, a novel LRP1 agonist, leads to cardioprotective signaling, significant reduction in infarct size, and preservation of cardiac function in myocardial ischemiareperfusion injury.
LRP1 is a membrane receptor mostly known for being part of the low-density lipoprotein receptor family and responsible for lipoprotein scavenging (3) (4) (5) . LRP1 is, however, a multifunctional protein (6) (7) (8) . LRP1, also known as A2MG receptor, is known to bind A2MG-protease complexes, and more in general binds SECs, acting as an SEC receptor (4,13,14) . The binding of LRP1 We induced acute myocardial infarction (AMI) in adult male mice by coronary ligation and transient ischemia (30 min) followed by reperfusion.
When compared with vehicle solution, SP16, but not SP34, given intraperitoneally at reperfusion significantly reduced in a dose-dependent fashion infarct size, measured as percent of area at risk at tetrazolium chloride (TTC) staining at pathology and preserved left ventricular systolic function measured as left ventricular (LV) fractional shortening (LVFS) %. n ¼ 5 to 8 mice/group. c-Trop I ¼ cardiac troponin I;
LVEDD ¼ left ventricular end-diastolic diameter; LVESD ¼ left ventricular end-systolic diameter.
LRP1 in AMI
to the enzyme-inhibitor complex acts not only as a scavenger but also as impacting anti-inflammatory and prosurvival signaling (3) (4) (5) (6) (7) (8) . In leukocytes, LRP1, also known as CD91, functions as scavenger receptor for apoptotic cells leading to an anti-inflammatory signal (19) . LRP1/CD91 is also involved in antigen showing that when LRP1-mediated protective effect is blocked, AAT may exert a toxic rather than a cardioprotective effect, through a different mechanism.
In the current study, we also show that SP16 is effective when tested in a clinically relevant setting.
In fact, the treatment was administered not before the onset of ischemia, which would not be feasible in Without reperfusion, the infarct size is predicted to represent approximately 70% of the myocardium at ischemic risk (27) . Reperfusion alone is predicted to double the amount of salvaged myocardium and reduce infarct size in half (27) . However, Kloner et al. TRANSLATIONAL OUTLOOK 2: LRP1 agonists can be developed to reduce myocardial ischemic injury. Synthetic LRP1 agonists may be advantageous, as they can be synthesized at low cost, and they lack the structural complexity to induce immunogenicity. Moreover, given the small molecular weight, they can be delivered subcutaneously. LRP1 in AMI
